Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Drusano, George L ^a   Neely, Michael ^b   Van Guilder, Michael ^b   Schumitzky, Alan ^b   Brown, David ^a   Fikes, Steven ^a   Peloquin, Charles ^c   Louie, Arnold ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ADDITIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; EMERGENCE OF RESISTANCE; HOLLOW FIBER; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SHORTENED THERAPY DURATION; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; THEORETICAL MODEL; TIME;

ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; LINEZOLID; MODELS, THEORETICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TIME FACTORS; TUBERCULOSIS;

EID: 84903888878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101311     Document Type: Article

References (32)

1. World Health Organization (2012) Global Tuberculosis Report. Geneva, Switzerland: WHO.
2. th edition. Geneva Switzerland: WHO.
3. FDA Package insert for bedaquiline. Available: http://www.accessdata.fda. gov/Scripts/cder/drugsatfda/index.cfm. Accessed: 2014 Jun 17.
4. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, et al. (2012) New Drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis. 205: S241-S249.
5. Grosset J, Tyagi S, Almeida DV, Converse PJ, Li SY, et al. (2013) Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med. 188:608-612.
6. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, et al. (2012) Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56: 5782-5789.
7. Selkon JB, Devadatta S, Kullarna KG, Mitchison DA, Narayana AS, et al. (1964) The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ. 31:273-94.
8. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, et al. (2009) Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother. . 53:4178-4184.
9. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, et al. (2010) The Combination of Rifampin plus Moxifloxacin is Synergistic for Resistance Suppression, but is Antagonistic for Cell Kill for Mycobacterium tuberculosis as Determined in a Hollow Fiber Infection Model. mBio 1:3 e00139-10.
10. Balasubramanian V, Solapure S, Gaonkar S, Mahesh Kumar KN, Shandil RK, et al. (2012) Effect of Co-administration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model. Antimicrob Agents Chemother 56:3054-3057.
11. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, et al. (2004) Selection of a Moxifloxacin Dose that Suppresses Mycobacterium tuberculosis Resistance Using an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling. J Infect Dis 190:1642-1651. (Pubitemid 39411014)
12. Gumbo T, Louie A, Deziel MR, Drusano GL (2005) Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill, but to rapid emergence of resistance. Antimicrob Agents Chemother 49:3178-3181. (Pubitemid 41060557)
13. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, et al. (2007) Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 195:194-201. (Pubitemid 46080051)
14. Gumbo T, Louie A, Brown D, Ambrose PG, Bhavnani SM, et al. (2007) Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 51: 2329-2336. (Pubitemid 47047307)
15. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, et al. (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51:3781-3788. (Pubitemid 350057771)
16. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, et al. (2011) Effect of administering moxifloxacin plus rifampin against Mycobacterium tuberculosis 7 of 7 Days versus 5 of 7 Days in an in Vitro pharmacodynamic system. mBio. 2:e00108-11.
17. Lee M, Lee J, Carroll MW, Choi H, Min S, et al. (2012) Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 367:1508-1518.
18. Greco WR, Bravo G, Parsons JC (1995). The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
19. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R (2003) Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 51:1431-1434. (Pubitemid 36748935)
20. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, et al. (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529-1533. (Pubitemid 40980608)
21. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, et al. (2009) Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 53;2974-2981.
22. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, et al. (2009) Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 53:3981-3984.
23. Ahmed I, Jabeen K, Inayat R, Hasan R. (2013) Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid and amoxicillin-clavulanate. Antimicrob Agents Chemother. 57:2511-2525.
24. Van Klingern B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen D. (2007) Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol. 45: 2662-2668. (Pubitemid 47295501)
25. th Conference on Retroviruses and Opportunistic Infections. March 3-6. Atlanta, GA.
26. Peloquin C (2003) What is the "right" dose of rifampin? Int J Tuberc Lung Dis. 7:3-5.
27. Blaser J (1985) In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother. 15 Suppl A:125-130.
28. Leary RH, Jelliffe R, Schumitzky A, Van Guilder M (2001) An adaptive grid non-parametric approach to population pharmacokinetic/dynamic (PK/PD) population models. Proceedings, 14th IEEE symposium on Computer Based Medical Systems 1:389-394.
29. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, et al. (2003) Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112:275-285. (Pubitemid 38056363)
30. D'Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles.
31. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW (2012) Accurate Detection of Outliers and Subpopulations with Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R. Therapeutic Drug Monitoring. 34:467-476.
32. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A (2009) Differing effect of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance on wild-type Pseudomonas aeruginosa PA01 and its isogenic MexAB efflux pump over-expressed mutant. Antimicrob Agents Chemother. 53:2266-2273.